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2141This article provides a brief summary of the relevant recommen-
dations and references related to percutaneous mechanical circu-
latory support. The goal was to provide the clinician with concise,
evidence-based contemporary recommendations, and the sup-
porting documentation to encourage their application. The full
text includes disclosure of all relevant relationships with industry
for each writing committee member. A fundamental aspect of all
expert consensus statements is that these carefully developed,
evidence-based documents can neither encompass all clinical cir-
cumstances, nor replace the judgment of individual physicians in
management of each patient. The science of medicine is rooted in
evidence, and the art of medicine is based on the application of this
evidence to the individual patient. This expert consensus state-
ment has adhered to these principles for optimal management of
patients requiring percutaneous mechanical circulatory support.
Although historically the intra-aortic balloon pump has
been the only mechanical circulatory support device
(MCS) available to clinicians, a number of new devices
have become commercially available and have entered
clinical practice. These include axial ﬂow pumps, such as
Impella; left atrial to femoral artery bypass pumps, spe-
ciﬁcally the TandemHeart; and new devices for institution
of extracorporeal membrane oxygenation (ECMO). These
devices differ signiﬁcantly in their hemodynamic effects,
insertion, monitoring, and clinical applicability. The full
text document reviews the physiologic impact on the cir-
culation of these devices and their use in speciﬁc clinical
situations (1). These situations include patients undergo-
ing high-risk percutaneous coronary intervention (PCI),
those presenting with cardiogenic shock, and acute
decompensated heart failure. Specialized uses for right-
sided support and in pediatric populations are discussed.
The clinical utility of MCS devices is reviewed as are the
American College of Cardiology/American Heart Associa-
tion clinical practice guidelines.
We provide the following consensus-based recommen-
dations based on the anticipated hemodynamic effects and
risks, clinical outcomes data as well as knowledge gaps.
1. Percutaneous MCS provides superior hemodynamic
support compared to pharmacologic therapy. This is
particularly apparent for the Impella and Tandem-
Heart devices. These devices should remain avail-
able clinically and be appropriately reimbursed.
2. Patients in cardiogenic shock represent an extremely
high-risk group in whom mortality has remained
high despite revascularization and pharmacologic
therapies. Early placement of an appropriate MCS
may be considered in those who fail to stabilize orshow signs of improvement quickly after initial
interventions.
3. MCS may be considered for patients undergoing high-
risk PCI, such as those requiring multivessel, left
main or last patent conduit interventions, particularly
if the patient is inoperable or has severely decreased
ejection fraction or elevated cardiac-ﬁlling pressures.
4. In the setting of profound cardiogenic shock, intra-
aortic balloon pump (IABP) is less likely to provide
beneﬁt than continuous ﬂow pumps including the
Impella CP and TandemHeart. ECMO may also provide
beneﬁt, particularly for patients with impaired respi-
ratory gas exchange.
5. Patients with acute decompensated heart failure may
beneﬁt from early use of percutaneous MCS when
they continue to deteriorate despite initial interven-
tions. MCS may be considered if patients are candi-
dates for surgically implanted ventricular assist device
(VAD) or if rapid recovery is expected (e.g., fulminant
myocarditis or stress-induced cardiomyopathy).
6. When oxygenation remains impaired, adding an oxy-
genator to a TandemHeart circuit or use of ECMO
should be considered based on local availability.
7. There are insufﬁcient data to support or refute the notion
that routine use of MCSs as an adjunct to primary revas-
cularization in the setting of large acute myocardial
infarction is useful in reducing reperfusion injury or
infarct size. Exploratory studies are underway.
8. MCSsmaybeused for failure toweanoff cardio-pulmonary
bypass, considered as an adjunct to high-risk electrophysi-
ologic procedures when prolonged hypotension is antici-
pated or, rarely, for valvular interventions.
9. Severe biventricular failure may require use of both
right- and left-sided percutaneous MCS or veno-
arterial ECMO. Certain patients may respond to left
ventricular assist device (LVAD) implantation with
inotropes and/or pulmonary vasodilators to support
the right heart. MCS may also be considered for iso-
lated acute right ventricular failure complicated by
cardiogenic shock.
10. Registries and randomized controlled trials comparing
different strategies in different clinical scenarios are
critically needed.
11. Early analyses suggest cost-effectiveness of MCS for
emergent use in comparison to surgical ECMO or VAD
support, and for elective use in comparison to IABP.
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